Browse PRDM1

Summary
SymbolPRDM1
NamePR domain containing 1, with ZNF domain
Aliases PRDI-BF1; BLIMP1; B-lymphocyte-induced maturation protein 1; BLIMP-1; PRDI-binding factor-1; beta-interferon ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm
Domain PF00856 SET domain
Function

Transcription factor that mediates a transcriptional program in various innate and adaptive immune tissue-resident lymphocyte T cell types such as tissue-resident memory T (Trm), natural killer (trNK) and natural killer T (NKT) cells and negatively regulates gene expression of proteins that promote the egress of tissue-resident T-cell populations from non-lymphoid organs. Plays a role in the development, retention and long-term establishment of adaptive and innate tissue-resident lymphocyte T cell types in non-lymphoid organs, such as the skin and gut, but also in other nonbarrier tissues like liver and kidney, and therefore may provide immediate immunological protection against reactivating infections or viral reinfection (By similarity). Binds specifically to the PRDI element in the promoter of the beta-interferon gene (PubMed:1851123). Drives the maturation of B-lymphocytes into Ig secreting cells (PubMed:12626569). Associates with the transcriptional repressor ZNF683 to chromatin at gene promoter regions (By similarity).

> Gene Ontology
 
Biological Process GO:0001654 eye development
GO:0001701 in utero embryonic development
GO:0001754 eye photoreceptor cell differentiation
GO:0001763 morphogenesis of a branching structure
GO:0001779 natural killer cell differentiation
GO:0001865 NK T cell differentiation
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0001893 maternal placenta development
GO:0002064 epithelial cell development
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0002066 columnar/cuboidal epithelial cell development
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002521 leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002831 regulation of response to biotic stimulus
GO:0002832 negative regulation of response to biotic stimulus
GO:0003170 heart valve development
GO:0003205 cardiac chamber development
GO:0003231 cardiac ventricle development
GO:0003279 cardiac septum development
GO:0003281 ventricular septum development
GO:0007159 leukocyte cell-cell adhesion
GO:0007281 germ cell development
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0007565 female pregnancy
GO:0009791 post-embryonic development
GO:0022407 regulation of cell-cell adhesion
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0030098 lymphocyte differentiation
GO:0030101 natural killer cell activation
GO:0030183 B cell differentiation
GO:0030217 T cell differentiation
GO:0030888 regulation of B cell proliferation
GO:0030889 negative regulation of B cell proliferation
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0031664 regulation of lipopolysaccharide-mediated signaling pathway
GO:0031665 negative regulation of lipopolysaccharide-mediated signaling pathway
GO:0032102 negative regulation of response to external stimulus
GO:0032259 methylation
GO:0032496 response to lipopolysaccharide
GO:0032814 regulation of natural killer cell activation
GO:0032823 regulation of natural killer cell differentiation
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032945 negative regulation of mononuclear cell proliferation
GO:0033078 extrathymic T cell differentiation
GO:0033082 regulation of extrathymic T cell differentiation
GO:0035904 aorta development
GO:0042100 B cell proliferation
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042461 photoreceptor cell development
GO:0042462 eye photoreceptor cell development
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0044706 multi-multicellular organism process
GO:0045165 cell fate commitment
GO:0045577 regulation of B cell differentiation
GO:0045579 positive regulation of B cell differentiation
GO:0045580 regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0046530 photoreceptor cell differentiation
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046651 lymphocyte proliferation
GO:0048514 blood vessel morphogenesis
GO:0048565 digestive tract development
GO:0048568 embryonic organ development
GO:0048592 eye morphogenesis
GO:0048608 reproductive structure development
GO:0048844 artery morphogenesis
GO:0050670 regulation of lymphocyte proliferation
GO:0050672 negative regulation of lymphocyte proliferation
GO:0050863 regulation of T cell activation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050869 negative regulation of B cell activation
GO:0050871 positive regulation of B cell activation
GO:0051136 regulation of NK T cell differentiation
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0055123 digestive system development
GO:0060135 maternal process involved in female pregnancy
GO:0060575 intestinal epithelial cell differentiation
GO:0060576 intestinal epithelial cell development
GO:0060706 cell differentiation involved in embryonic placenta development
GO:0060707 trophoblast giant cell differentiation
GO:0060840 artery development
GO:0060976 coronary vasculature development
GO:0061458 reproductive system development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070664 negative regulation of leukocyte proliferation
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071593 lymphocyte aggregation
GO:0090596 sensory organ morphogenesis
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1990654 sebum secreting cell proliferation
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0008168 methyltransferase activity
GO:0016741 transferase activity, transferring one-carbon groups
GO:0042826 histone deacetylase binding
GO:1990841 promoter-specific chromatin binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804754: Regulation of TP53 Expression
R-HSA-6806003: Regulation of TP53 Expression and Degradation
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolPRDM1
NamePR domain containing 1, with ZNF domain
Aliases PRDI-BF1; BLIMP1; B-lymphocyte-induced maturation protein 1; BLIMP-1; PRDI-binding factor-1; beta-interferon ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PRDM1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PRDM1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25347474Lung CarcinomaPromote immunity (T cell function)We determined that tumor-derived TGF-β directly suppresses CTL immune function by elevating miR-23a and downregulating BLIMP-1. Functional blocking of miR-23a in human CTLs enhanced granzyme B expression, and in mice with established tumors, immunotherapy with just a small number of tumor-specific CTLs in which miR-23a was inhibited robustly hindered tumor progression.
24637363Chronic Lymphocytic LeukemiaPromote immunityVariable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy. PRDM1 induction was inversely correlated with the extent of anergy as measured by the ability to mobilize intracellular Ca(2+) following BCR crosslinking. Epigenetic drugs may offer possibilities to reactivate PRDM1 expression as part of novel differentiation therapy approaches.
Summary
SymbolPRDM1
NamePR domain containing 1, with ZNF domain
Aliases PRDI-BF1; BLIMP1; B-lymphocyte-induced maturation protein 1; BLIMP-1; PRDI-binding factor-1; beta-interferon ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PRDM1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPRDM1
NamePR domain containing 1, with ZNF domain
Aliases PRDI-BF1; BLIMP1; B-lymphocyte-induced maturation protein 1; BLIMP-1; PRDI-binding factor-1; beta-interferon ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PRDM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2210.591
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0450.965
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3470.653
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1530.613
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3250.868
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0690.979
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1030.825
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2610.818
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0670.957
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.080.222
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.790.147
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1230.399
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PRDM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPRDM1
NamePR domain containing 1, with ZNF domain
Aliases PRDI-BF1; BLIMP1; B-lymphocyte-induced maturation protein 1; BLIMP-1; PRDI-binding factor-1; beta-interferon ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRDM1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPRDM1
NamePR domain containing 1, with ZNF domain
Aliases PRDI-BF1; BLIMP1; B-lymphocyte-induced maturation protein 1; BLIMP-1; PRDI-binding factor-1; beta-interferon ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRDM1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRDM1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPRDM1
NamePR domain containing 1, with ZNF domain
Aliases PRDI-BF1; BLIMP1; B-lymphocyte-induced maturation protein 1; BLIMP-1; PRDI-binding factor-1; beta-interferon ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRDM1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPRDM1
NamePR domain containing 1, with ZNF domain
Aliases PRDI-BF1; BLIMP1; B-lymphocyte-induced maturation protein 1; BLIMP-1; PRDI-binding factor-1; beta-interferon ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PRDM1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPRDM1
NamePR domain containing 1, with ZNF domain
Aliases PRDI-BF1; BLIMP1; B-lymphocyte-induced maturation protein 1; BLIMP-1; PRDI-binding factor-1; beta-interferon ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PRDM1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPRDM1
NamePR domain containing 1, with ZNF domain
Aliases PRDI-BF1; BLIMP1; B-lymphocyte-induced maturation protein 1; BLIMP-1; PRDI-binding factor-1; beta-interferon ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PRDM1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.